United States Patent 4,659,716 (Scope, Claim Coverage, and US Patent Landscape)
US Patent 4,659,716 is directed to substituted heterocyclic compounds (where X is Cl or F) and their pharmaceutically acceptable salts, paired with broad pharmaceutical product claims (antihistaminic compositions, unit dosage forms) and method-of-use claims for treating allergic reactions. The claim set also expressly claims specific salt and specific disclosed structural embodiments tied to claims 3 and 4, plus transdermal formulations.
What does US 4,659,716 claim: compound definitions, salts, formulations, and methods?
Answer: The patent claims (i) a core chemical structure limited to X = Cl or F, (ii) an acetic acid salt embodiment, (iii) at least two specific structural formula embodiments, (iv) antihistaminic compositions with pharmaceutically acceptable carriers, (v) unit dosage forms for two embodiments, (vi) transdermal compositions for three embodiments, and (vii) methods of treating allergic reactions by administering the claimed compounds.
Core compound claim scope: claim 1 (X = Cl or F)
- Claim 1 covers “a compound of the formula … wherein X represents Cl or F” or a pharmaceutically acceptable salt.
- Practical scope impact
- The claim is structure-limited by the formula shown in the patent’s specification (not reproduced in your prompt).
- The “X = Cl or F” limitation narrows halogen substitution to these two specific substituents.
- Because salts are included, infringement can be triggered by either the free base (if it exists) or a covered salt form.
Design-around pressure point: any compound with the same scaffold but X = Br, I, or hydrogen falls outside claim 1 as written, unless captured by claims 3 or 4 (which depend on the specific structures shown in the patent).
Salt coverage: claim 2 (acetic acid salt)
- Claim 2 narrows claim 1 to “the acetic acid salt.”
- Implication
- A product using a different pharmaceutically acceptable salt (e.g., HCl, citrate, maleate, fumarate) avoids claim 2 while remaining potentially in claim 1 (if the underlying compound matches the claim 1 structure).
- If a competitor markets only a non-acetic acid salt, claim 2 may not apply, but claims 1 (and likely claims 5-8, 11-16 depending on the specific embodiments) may still apply.
Specific structural embodiments: claims 3 and 4
- Claim 3 covers “a compound having the structural formula … or a pharmaceutically acceptable salt thereof.”
- Claim 4 covers “a compound having the structural formula … or a pharmaceutically acceptable salt thereof.”
- Practical scope impact
- These claims appear to capture particular members within the broader class of claim 1 or likely capture named/illustrated compounds from the specification.
- In an infringement analysis, claims 3 and 4 can be stronger than claim 1 because they tie to a specific structure, and they are the anchor for multiple downstream composition and transdermal claims.
Key consequence: if a competitor’s compound does not satisfy the claim 1 “X = Cl or F” formula boundary, it could still be captured if it matches the exact structures in claims 3 or 4.
Downstream product coverage: claims 5–13
The patent builds a typical pharmaceutical IP chain:
- compound
- formulation
- unit dose form
- transdermal formulation
Antihistaminic compositions
- Claim 5: antihistaminic composition comprising an effective amount of a claim 1 compound + pharmaceutically acceptable carrier.
- Claim 6: same, but for claim 2 compound (acetic acid salt).
- Claim 7: composition for claim 3 compound.
- Claim 8: composition for claim 4 compound.
These claims are broad in that they do not limit excipients, dosage strength, release profile, or route beyond “antihistaminic effective amount” and “carrier.”
Unit dosage form
- Claim 9: unit dosage form for the claim 3 composition.
- Claim 10: unit dosage form for the claim 4 composition.
This narrows to dosage form presentation, but still typically allows any unit dosing packaging (tablets, capsules, powders) unless the specification imposes limits.
Transdermally acceptable compositions
- Claim 11: transdermal composition for claim 1 compound + pharmaceutically acceptable transdermal carrier.
- Claim 12: transdermal composition for claim 3 compound.
- Claim 13: transdermal composition for claim 4 compound.
Scope note: “transdermally acceptable transdermal carrier” is a broad formulation category. It likely covers a wide range of penetration enhancers, adhesives, and matrix systems unless excluded by the specification’s examples.
Method-of-use coverage: claims 14–16
- Claim 14: treating allergic reactions in a mammal by administering an anti-allergic effective amount of a claim 1 compound.
- Claim 15: same, for claim 3 compound.
- Claim 16: same, for claim 4 compound.
These are treatment-use claims. The infringement trigger is the clinical use and administration of the compound for the claimed indication.
Commercial implication: even if a competitor’s formulation is non-infringing on composition claims (e.g., different carrier route), method-of-use exposure remains if the product is used to treat allergic reactions and the asserted compound matches claims 1/3/4.
How broad are the claims and where are the likely infringement and design-around edges?
Answer: The estate is broad on compound-class membership (claim 1: X = Cl or F), broad on formulation and carrier (claims 5–8, 11–13), and broad on method-of-use (claims 14–16). The most meaningful design-around is shifting the halogen away from Cl/F or using a non-matching specific structural embodiment for claims 3 and 4.
Most likely infringement levers
- Exact scaffold match to the claim 1 formula with X = Cl or F.
- Selling or using salt forms that fall under “pharmaceutically acceptable salts” (claim 1) and specifically the acetic acid salt (claim 2).
- Marketing antihistaminic and transdermal products containing the claim compounds in effective amounts (claims 5–8, 11–13).
- Clinical use for “allergic reactions” (claims 14–16).
Most likely design-around levers
- Altering the halogen position or value so that X is not Cl or F.
- Avoiding the specific structural formula members in claims 3 and 4 (if those are tighter than claim 1).
- Using a different salt form to avoid claim 2 (acetic acid salt), though claim 1 would remain a risk if the underlying free base/salt is covered as a pharmaceutically acceptable salt.
How many distinct invention “buckets” does US 4,659,716 cover?
Answer: At least 5 buckets: (1) core compound class, (2) acetic acid salt, (3) two specific structural embodiments, (4) antihistaminic compositions including unit dose presentation, and (5) transdermal and method-of-use treatment claims.
Bucket-to-claim mapping
| Bucket |
Claims |
What they cover |
| Core compound class |
1 |
Compound with X = Cl or F + pharmaceutically acceptable salt |
| Specific salt |
2 |
Acetic acid salt of the claim 1 compound |
| Specific structural embodiments |
3, 4 |
Two specific structural formula compounds + salts |
| Antihistaminic compositions |
5, 7, 8 (and 6 for salt) |
Effective antihistaminic compositions with carriers |
| Transdermal and treatment |
11–16 |
Transdermal compositions and method-of-treatment of allergic reactions |
What patents likely exist around US 4,659,716 (US continuation, related filings, and claim evolution)?
Answer: Based on the claim structure, US 4,659,716 likely sits within a family where the specification describes at least two specific compounds (claims 3 and 4) and demonstrates formulation feasibility for antihistaminic and transdermal dosage forms. Typically, related US filings would include:
- continuations with narrower composition claims (specific carriers, dosage regimens),
- continuation-in-part style additions (new salts, new routes such as transdermal patches),
- and method claims keyed to “allergic reactions” treatment.
However, no complete family map is provided in the prompt, and the exact compound identity (drug name, scaffold, assignee) is not supplied. Without the assignee/inventor, publication numbers, or the patent’s title, it is not possible to accurately enumerate related US patents in the family or the broader landscape with hard citations.
What is the infringement risk profile by product type: API, salt form, formulation, transdermal, and method use?
Answer: Highest risk is from products that use a claim 1/3/4 compound in either oral or transdermal antihistaminic formulations, and any clinical promotion or use for treating allergic reactions. Risk drops only when the compound does not fall within the structural limits of claim 1 or does not match claims 3/4.
API-only vs finished dosage
- API manufacturer: If supplying a covered compound (X = Cl or F) that is a “compound of formula,” API alone can support exposure for downstream formulation and method claims.
- Salt suppliers: acetic acid salt products are directly in claim 2; other pharmaceutically acceptable salts remain in claim 1 if they fall under the claim 1 salt definition.
- Formulation manufacturers: broad carrier language makes most conventional antihistaminic excipient choices look within claims 5–8.
- Transdermal dosage manufacturers: claims 11–13 capture “transdermally acceptable” compositions with transdermal carriers. A patch, gel, or similar system is likely within the claim if the API is covered.
Method-of-use exposure
- If prescribers use the compound to treat allergic reactions, claims 14–16 are implicated regardless of the carrier, unless the product is not administered as the claimed compound or the use is outside “allergic reactions” as framed by the patent.
How does US 4,659,716 compare with typical antihistamine/transdermal patent estates?
Answer: The estate aligns with “compound + salt + composition + route + indication” coverage. That structure is favorable for enforcement because it captures both formulation and use.
Strength drivers
- Broad “effective amount” and “pharmaceutically acceptable carrier” language.
- Separate transdermal route claims.
- Dedicated method claims tied to allergic reactions.
- Inclusion of pharmaceutically acceptable salts and a specific acetic acid salt.
Potential weak points
- The main compound limitation depends on the exact chemical formula in the patent drawings.
- If claims 3 and 4 are narrow to specific compounds, a competitor can avoid them by targeting non-matching members, while still potentially risking claim 1 depending on the X substitution and formula scope.
Key Takeaways
- US 4,659,716 claims a structured class of substituted compounds with X = Cl or F, plus pharmaceutically acceptable salts.
- The patent explicitly includes the acetic acid salt (claim 2).
- It covers antihistaminic compositions and unit dosage forms for specific structural embodiments (claims 5–10).
- It extends to transdermal compositions (claims 11–13).
- It includes method-of-use protection for treating allergic reactions in mammals (claims 14–16).
- The core design-around hinge is avoiding the claim 1 scaffold limits (particularly the Cl/F substitution) and avoiding the exact structural embodiments recited in claims 3 and 4.
FAQs
-
Can a competitor avoid US 4,659,716 by switching from acetic acid salt to another pharmaceutically acceptable salt?
Claim 2 is specific to acetic acid salt, but claim 1 covers pharmaceutically acceptable salts of the claim 1 compound, so changing only the salt may not remove risk.
-
Does US 4,659,716 cover transdermal formulations even if the product is not an oral antihistamine?
Yes. Claims 11–13 expressly cover transdermally acceptable pharmaceutical compositions.
-
If a generic launches a covered API, which claims create the biggest litigation exposure: formulation or method-of-use?
Composition claims (5–8, 11–13) and method-of-use claims (14–16) both create exposure because the claims are independent and cover different infringement theories.
-
Are the unit dosage form claims tied to a specific route like oral tablets only?
The prompt shows unit dosage form claims 9 and 10 but does not specify route. Unit dosage presentation is claimed for compositions of claims 7 and 8.
-
What is the most direct chemical design-around for claim 1?
Using a compound where X is not Cl or F, assuming the competitor’s compound does not match the structures in claims 3 or 4.
References (APA)
- United States Patent No. 4,659,716.
